Bemfola

RSS

follitropin alfa

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Bemfola. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Bemfola.

For practical information about using Bemfola, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 10/01/2019

Authorisation details

Product details
Name
Bemfola
Agency product number
EMEA/H/C/002615
Active substance
follitropin alfa
International non-proprietary name (INN) or common name
follitropin alfa
Therapeutic area (MeSH)
Anovulation
Anatomical therapeutic chemical (ATC) code
G03GA05
Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Publication details
Marketing-authorisation holder
Gedeon Richter Plc.
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
26/03/2014
Contact address
Gyomroi ut 19-21
1103 Budapest
Hungary

Product information

12/11/2018 Bemfola - EMEA/H/C/002615 - R/0019

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

In adult women:

  • anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate;
  • stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT);
  • follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/l.

In adult men:

  • follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.

Assessment history

How useful was this page?

Add your rating